Targeting cancer stem cells by disulfiram and copper sensitizes radioresistant chondrosarcoma to radiation

Kun Wang,Theodoros Michelakos,Bing Wang,Zikun Shang,Albert B. DeLeo,Zhenfeng Duan,Francis J. Hornicek,Joseph H. Schwab,Xinhui Wang
DOI: https://doi.org/10.1016/j.canlet.2021.02.002
IF: 9.756
2021-05-01
Cancer Letters
Abstract:<p>Overcoming the radiosensitivity of chondrosarcoma (CS), the second most common primary bone tumor, is needed. Radioresistance is attributed to cancer stem cells (CSCs) in many malignancies. Disulfiram (DSF), an FDA-approved anti-alcoholism drug, complexed with Cu (DSF/Cu) can radiosensitize epithelial CSCs. This prompted us to investigate the radiosensitizing effect of DSF/Cu on CS CSCs (CCSCs). The radiosensitizing effects of DSF/Cu on CCSCs were investigated <em>in vitro</em> using cell lines SW1353 and CS-1. Stemness was identified independently with flow cytometry for CCSCs (ALDH<sup>+</sup>CD133<sup>+</sup>), sphere-forming ability, and Western blot analysis of stemness gene protein expression The radiosensitizing effect of DSF/Cu was studied in an orthotopic CS xenograft mouse model by analyzing xenograft growth and residual xenografts for stemness. CCSCs were resistant to single-dose (IR) and fractionated irradiation (FIR). IR and FIR increased CS stemness. Combined with DSF/Cu <em>in vitro</em> and <em>in vivo</em>, IR and FIR eliminated CS stemness. RT + DSF/Cu was safer and more effective than either RT ± DSF in inhibiting growth of orthotopic CS xenografts. In conclusion, DSF/Cu radiosensitizes CCSCs. These results can be translated into clinical trials for CS patients requiring RT for improved outcomes.</p>
oncology
What problem does this paper attempt to address?